Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.

Studied

SUSTAIN 7 was a randomized, open-label phase 3b trial comparing weekly semaglutide with dulaglutide; HbA1c and body weight were assessed at week 40.

Who / model

Participants were adults with type 2 diabetes inadequately controlled on metformin alone.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

At the lower-dose comparison, body weight fell by 4.6 kg with semaglutide and 2.3 kg with dulaglutide.

Limits

The study was open-label. Gastrointestinal disorders were the most common reason for discontinuation, and six fatalities occurred across the four groups.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary